{
  "id": "5c6dfdf27c78d69471000047",
  "type": "list",
  "question": "List drugs that were tested in the CheckMate 214 trial.",
  "ideal_answer": "CheckMate 214 clinical trial compared Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29562145",
    "http://www.ncbi.nlm.nih.gov/pubmed/29587324",
    "http://www.ncbi.nlm.nih.gov/pubmed/29728867",
    "http://www.ncbi.nlm.nih.gov/pubmed/30332546",
    "http://www.ncbi.nlm.nih.gov/pubmed/29223605",
    "http://www.ncbi.nlm.nih.gov/pubmed/30187355",
    "http://www.ncbi.nlm.nih.gov/pubmed/29468108"
  ],
  "snippets": [
    {
      "text": " In 2015, the pivotal phase III study CheckMate 025 led to the Food and Drug Administration approval of nivolumab in patients with aRCC who had received prior anti-angiogenic therapy, and in 2017, the phase III study CheckMate 214 showed that combined immunotherapy with nivolumab plus ipilimumab resulted in greater objective response rate and prolonged progression-free survival when compared with sunitinib in intermediate- and poor-risk patients with previously untreated aRCC",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29468108",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29562145",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma.METHODS: We randomly assigned adults in a 1:1 ratio to receive either nivolumab (3 mg per kilogram of body weight) plus ipilimumab (1 mg per kilogram) intravenously every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) every 2 weeks, or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29562145",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previously untreated advanced renal-cell carcinoma. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 214 ClinicalTrials.gov number, NCT02231749 .).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29562145",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Out of these CheckMate 214, a randomized phase-3 trial is the first to demonstrate a significant higher objective response rate (42\u200a% vs. 27\u200a%, p\u200a<\u200a0.0001) and overall survival (Sunitinib 26.0 month, median for Nivo\u200a+\u200aIpi has been not yet reached (28.2\u200a-\u200aNR); Hazard ratio 0.63) for the combination of Nivolumab and the CTLA-4 antibody Ipilimumab in IMDC intermediate and high risk patients. Furthermore, CheckMate 214 shows better side effect profile and quality of life in patients receiving Nivolumab and Ipilimumab compared with Sunitinib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29587324",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CheckMate 214, a phase III trial, demonstrated superior overall survival and objective response with combined checkpoint inhibitors compared to sunitinib in Treatment-Na\u00efve Advanced RCC among intermediate- and poor-risk group (Motzer et al. in N Engl J Med. 378(14):1277-1290, 2018).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29728867",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "First, the CheckMate 214 trial demonstrated an objective response rate and overall survival benefit for the combination of nivolumab plus ipilimumab in the intermediate- and poor-risk patients. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30187355",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "have recently published in the New England Journal of Medicine the findings of CheckMate 214 trial, using nivolumab and ipilimumab, a cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitor, versus sunitinib in previously untreated advanced RCC. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30332546",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CheckMate 214: efficacy and safety of nivolumab plus ipilimumab vs sunitinib for treatment-na\u00efve advanced or metastatic renal cell carcinoma, including IMDC risk and PD-L1 expression subgroups.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29223605",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The randomised phase III clinical trial Checkmate-214 showed a survival superiority for the combination of ipilimumab and nivolumab when compared with the previous standard of care in first-line metastatic/advanced clear cell renal cell carcinoma (RCC) (Escudier B, Tannir NM, McDermott DF, et al.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29223605",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Out of these CheckMate 214, a randomized phase-3 trial is the first to demonstrate a significant higher objective response rate (42\u200a% vs. 27\u200a%, p\u200a<\u200a0.0001) and overall survival (Sunitinib 26.0 month, median for Nivo\u200a+\u200aIpi has been not yet reached (28.2\u200a-\u200aNR); Hazard ratio 0.63) for the combination of Nivolumab and the CTLA-4 antibody Ipilimumab in IMDC intermediate and high risk patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29587324",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Furthermore, CheckMate 214 shows better side effect profile and quality of life in patients receiving Nivolumab and Ipilimumab compared with Sunitinib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29587324",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CheckMate 025, the prospective randomized trial which led to approval of Nivolumab demonstrated improved overall survival (26 month vs. 19.7 month; hazard ratio 0.73; p\u200a=\u200a0.0006) and response rate (26\u200a% vs. 5\u200a%) as well as a favorable toxicity profile compared with Everolimus.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29587324",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In 2015, the pivotal phase III study CheckMate 025 led to the Food and Drug Administration approval of nivolumab in patients with aRCC who had received prior anti-angiogenic therapy, and in 2017, the phase III study CheckMate 214 showed that combined immunotherapy with nivolumab plus ipilimumab resulted in greater objective response rate and prolonged progression-free survival when compared with sunitinib in intermediate- and poor-risk patients with previously untreated aRCC.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29468108",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "have recently published in the New England Journal of Medicine the findings of CheckMate 214 trial, using nivolumab and ipilimumab, a cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitor, versus sunitinib in previously untreated advanced RCC.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30332546",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "First, the CheckMate 214 trial demonstrated an objective response rate and overall survival benefit for the combination of nivolumab plus ipilimumab in the intermediate- and poor-risk patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30187355",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CheckMate 214, a phase III trial, demonstrated superior overall survival and objective response with combined checkpoint inhibitors compared to sunitinib in Treatment-Na\u00efve Advanced RCC among intermediate- and poor-risk group (Motzer et al.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29728867",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Out of these CheckMate 214, a randomized phase-3 trial is the first to demonstrate a significant higher objective response rate (42\u200a% vs. 27\u200a%, p\u200a&lt;\u200a0.0001) and overall survival (Sunitinib 26.0 month, median for Nivo\u200a+\u200aIpi has been not yet reached (28.2\u200a-\u200aNR); Hazard ratio 0.63) for the combination of Nivolumab and the CTLA-4 antibody Ipilimumab in IMDC intermediate and high risk patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29587324",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Furthermore, CheckMate 214 shows better side effect profile and quality of life in patients receiving Nivolumab and Ipilimumab compared with Sunitinib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29587324",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Nivolumab, Ipilimumab, Sunitinib"
}